Kiniksa proposes redomicile from Bermuda to UK via scheme of arrangement; expects completion H2 2024

Kiniksa Pharmaceuticals International, plc

Proposes to change principal holding company incorporation from Bermuda to the UK by scheme of arrangement.
Shares exchanged 1:1 for new UK company shares; continues trading on Nasdaq under ticker KNSA.
Cites improved tax treaty access and protection from OECD/Bermuda tax initiatives as key reasons.
No material impact on financial results expected; completion targeted for second half 2024.
Convening hearing before Bermuda Supreme Court set for April 19, 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.